Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1999-08-19
2000-10-17
Ramsuer, Robert W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
564 49, 564 52, A61K 3117, A61P 1706, C07C27534
Patent
active
061333190
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to a novel group of phenyl urea compounds, processes for the preparation thereof, the use thereof in treating IL-8, GRO.alpha., GRO.beta., GRO.gamma., NAP-2 and ENA-78 mediated diseases and pharmaceutical compositions for use in such therapy.
BACKGROUND OF THE INVENTION
Many different names have been applied to Interleukin-8 (IL-8), such as neutrophil attractant/activation protein-1 (NAP-1), monocyte derived neutrophil chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor. Interleukin-8 is a chemoattractant for neutrophils, basophils, and a subset of T-cells. It is produced by a majority of nucleated cells including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF, IL-1.alpha., IL-1.beta. or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP. M. Baggiolini et al, J. Clin. Invest. 84, 1045 (1989); J. Schroder et al, J. Immunol. 139, 3474 (1987) and J. Immunol. 144, 2223 (1990); Strieter, et al, Science 243, 1467 (1989) and J. Biol. Chem. 264, 10621 (1989); Cassatella et al, J. Immunol. 148, 3216 (1992).
Gro.alpha., GRO.beta., GRO.gamma. and NAP-2 also belong to the chemokine a family. Like IL-8 these chemokines have also been referred to by different names. For instance Gro.alpha., GRO.beta., and GRO.gamma. have been referred to as MGSA.alpha., .beta. and .gamma. respectively (Melanoma Growth Stimulating Activity), see Richmond et al, J. Cell Physiology 129, 375 (1986) and Chang et al, J. Immunol 148, 451 (1992). All of the chemokines of the a-family which possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor.
treating IL-8, GRO.alpha., GRO.beta., GRO.gamma., NAP-2 and ENA-78 stimulate a number of functions in vitro. The have all been shown to have chemoattractant properties for neutrophils, while IL-8 and GROa have demonstrated T-lymphocytes, and basophiles chemotactic activity. In addition IL-8 can induce histamine release from basophils from both normal and atopic individuals GRO-.alpha. and IL-8 can in addition, induce lysozomal enzyme release and respiratory burst from neutrophils. IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils without de novo protein synthesis. This may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many known diseases are characterized by massive neutrophil infiltration. As IL-8, Gro.alpha., GRO.beta., GRO.gamma. and NAP-2 promote the accumulation and activation of neutrophils, these chemokines have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis, Baggiolini et al, FEBS Lett. 307, 97 (1992); Miller et al, Crit. Rev. Immunol. 12, 17 (1992); Oppenheim et al, Annu. Rev. Immunol. 9, 617 (1991); Seitz et al., J. Clin. Invest. 87, 463 (1991); Miller et al., Am. Rev. Respir. Dis. 146, 427 (1992); Donnely et al., Lancet 341, 643 (1993). In addition the ELR chemokines (those containing the amino acids ELR motif just prior to the CXC motif) have also been implicated in angiostasis. Strieter et al, Science 258, 1798 (1992).
In vitro, IL-8, Gro.alpha., GRO.beta., GRO.gamma. and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-linked family, in particular by binding to IL-8 receptors, most notably the B-receptor. Thomas et al., J. Biol. Chem. 266, 14839 (1991); and Holmes et al., Science 253, 1278 (1991). The development of non-peptide small molecule antagonists for members of this receptor family has precedent. For a review see R. Freidinger in: Progress in Drug Research, Vol. 40, pp. 33-98, Birkhauser Verlag, Basel 1993. Hence, the IL-8 receptor represents a promising target for the development of novel anti-inflammatory agents.
Two high affinity human IL-8 receptors (77% homology) have been characterized: IL-8Ra, which binds only
REFERENCES:
patent: 2363074 (1944-11-01), Martin et al.
patent: 3332981 (1967-07-01), Shultis, Jr. et al.
patent: 3689550 (1972-09-01), Schellenbaum et al.
patent: 3855285 (1974-12-01), Holland
patent: 3856951 (1974-12-01), Holland
patent: 3869553 (1975-03-01), Holland
patent: 3882230 (1975-05-01), Holland
patent: 3996253 (1976-12-01), Magnoli et al.
patent: 4048333 (1977-09-01), Galabov et al.
patent: 4405644 (1983-09-01), Kabbe et al.
patent: 4591604 (1986-05-01), Conrow et al.
patent: 4608205 (1986-08-01), Conrow et al.
patent: 5106873 (1992-04-01), O'Brien et al.
patent: 5275932 (1994-01-01), Weigel et al.
patent: 5312831 (1994-05-01), Ayral-Kaloustian et al.
patent: 5384319 (1995-01-01), Ferrini
patent: 5384330 (1995-01-01), Dieter et al.
patent: 5447957 (1995-09-01), Adams et al.
patent: 5470882 (1995-11-01), Dixon et al.
patent: 5585518 (1996-12-01), Marschner et al.
patent: 5621010 (1997-04-01), Sueda et al.
Howard, O.M.Z., et al., Chemokines: Progress toward Identifying Molecular Targets for Therapeutic Agents TIBECH pp., 46-51, vol. 14, 1996.
Lozanova et al., Dokl. Bulg. Akad. Nauk, 46(11), pp. 85-88 (1993).
Hauptman et al., Chemical Abstracts, vol. 109, No. 25, 1988, p. 816. Abstract No. 230,571k.
Hauptmann et al., Derwent Abstracts, vol. 88, Abstract No. 183601, 1988.
Broome et al., Ind Chem Belge, vol. 32, 1967.
Rao et al., J. Ind. Chem. Soc., vol. L, 492-4 (1973).
Tanaka et al. J. Agric. Food Chem, vol. 27 (2), 311-15, (1979).
Patil et al., Indian J. Pharm. Sci., vol. 49 (6), 229-231, (1987).
Warren et al., Drug Metab. Dispos., vol. 6 (1), 38-44, (1978).
Craig et al., Drug Metab. Dispos, vol. 17 (3), 345-347 (1989).
Jeffcoat et al., Drug Metab. Dispos, vol 5 (2), 157-66 (1980).
Hiles et al., Toxical. Appl. Pharm, vol. 46 (2), 323-37 (1978).
Carini et al., J. Med Chem, vol. 33 (5), 1330-6 (1990).
Gruenke et al., J. Anal Toxicol, vol. 11 (2), 75-80 (1987).
Sugihara, T., Nippon Kasei Gakkaishi, 43(3), 207-214 (1992).
Sugihara, T., Nippon Kasei Gakkaishi, 40(8), 691-6 (1989).
Roy, S. et al., Cell. Immunol., 105(1), 118-26 (1987).
Christove, A. et al., Dokl Bolg. Akad. Nauk. 39(3), 125-8 (1986).
Mashev, N. et al., Dokl Bolg. Akad. Nauk, 38(1), 107-9 (1985).
Schuster, G. et al., Z. Pflanzenkrankheiten, 90(5), 500-4 (1983).
Vassilev, G. et al., Dokl. Bolg. Akad. Nauk., 35(8), 1141-4 (1982).
Schuster, G., Wiss Z., Karl Marx Univ. Leipzig, Math, 31(4), 321-30 (1982).
Nakov, B. et al., Nauchni Tr., Vissh Selskostop. Inst. "Vasil Kolarov", 26(4), Plovdiv, 231-9 (1981).
Iwamura, Hajime, et al., Phytochemistry, 19(7), 1309-19 (1980).
Galabov, A. et al., J. Med. Chem., 23(9), 1048-51 (1980).
Mashev, N. et a., Dokl. Bolg. Akad. Nauk, 32 (11), 1555-8 (1979).
Galabov, A., Probl. Infect. Parasit. Dis., 7, 19-24 (1979).
Franke, R. et al., Dokl. Bolg. Akad. Nauk., 32(3), 369-71 (1979).
Krause G. et al., Biochem. Physiol. Pflanz., 174(2), 128-38 (1979).
Vassilev G. et al., Fiziol. Rast (Moscow), 25(5), 1070 (1978).
Vassilev G. et al., Plant Growth Regul., Proc. Int. Symp. 1975, mtg date, 511-14 (1977).
Galabov, A. et al., Chemotherapty (Basel), 23(2), 81-9 (1977).
Galabov A., Dokl. Bolg. Akad. Nauk, 29(8), 1219-22 (1976).
Radnev R. et al., Rastenievud. Nauki, 12 (8), 21-7 (1975).
Mashev N. et al., Fixiol. Rast. (Sofia), 1(2), 19-29 (1974).
Mashev N. et a., Dokl. Skh. Akad., Sofia, 7(1), 11-15 (1974).
Vassilev G.N. et al., Biochem Physiol. Pflanz., 165 (5/6), 467-78 (1974).
Galabov, A.S. et al., Antimicrob. Agents Chemother., 5(1), 108 (1974).
Galabov, A.S., Prof. Chemother., 2, 981-5 (1973).
Vassilev, G. et al., Izv. Inst. Fiziol. Rast., 18, 155-73 (1973).
Vassilev, G. et al., Arch. Phytopathol., 9(5), 309-20 (1973).
Vassilev, G. et al., Dokl. Bolg. Akad. Nauk, 26(4), 513-516 (1973).
Ivanova, Y.A. et al., Dokl. Bolg. Akad. Nauk, 25(8), 1101-4 (1972).
Ivanov, I.A. et al., Dokl. Bolg. Akad. Nauk, 25(6), 799-802 (1972).
Vassilev G.N. et al., Dokl. Bolg. Akad. Nauk, 25(7), 941-4 (1972).
Galabov, A. et al., Arach. Gesamte Virusforsch, 28(2-3), 159-66 (1972).
Galabov,
Dinner Dara L.
Kinzig Charles M.
Ramsuer Robert W.
Simon Soma G.
SmithKline Beecham Corporation
LandOfFree
IL-8 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-8 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-8 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-469654